Dr. Moore on the NOVA Trial for Ovarian Cancer

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the international, randomized phase III NOVA trial for recurrent platinum-sensitive ovarian cancer.

The NOVA trial aimed to determine whether the PARP inhibitor niraparib improves progression-free survival, with other endpoints being overall survival, time to first subsequent therapy, chemotherapy-free interval, and other quality-of-life measures.

This study allowed any patient with high-grade serous ovarian cancer to be split into 2 groups for independent studies.